Canagliflozin on Liver Inflammation Damage in Type 2 Diabetes Patients With Nonalcoholic Fatty Liver Disease
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05422092 |
Recruitment Status :
Not yet recruiting
First Posted : June 16, 2022
Last Update Posted : September 21, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Type 2 Diabetes Mellitus With Complication | Drug: Canagliflozin Drug: Pioglitazone | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 80 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Diagnostic |
Official Title: | Therapeutic Effects of Canagliflozin on the Liver Inflammation Damage and Lipoprotein Metabolism in Patients With Type 2 Diabetes Mellitus Combined With Nonalcoholic Fatty Liver Disease |
Estimated Study Start Date : | September 20, 2022 |
Estimated Primary Completion Date : | January 2023 |
Estimated Study Completion Date : | December 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Canagliflozin treatment group
Canagliflozin 100mg were given to the patients for 24 weeks
|
Drug: Canagliflozin
40 patients with T2DM combined with NAFLD, who have poor glycemic control response to metformin monotherapy, will be randomly assigned to receive canagliflozin on top of metformin as experimental group.
Other Name: Canagliflozin tablets |
Placebo Comparator: Pioglitazone treatment group
Pioglitazone 30mg were given to the patients and the dosage will be increased to 45mg 2 weeks later
|
Drug: Pioglitazone
40 patients with T2DM combined with NAFLD, who have poor glycemic control response to metformin monotherapy, will be randomly assigned to receive pioglitazone 45mg on top of metformin as placebo comparator group.
Other Name: Pioglitazone Hydrochloride Tablets |
- Plasma cholesteryl ester transfer protein(CETP) concentration in ug/mL [ Time Frame: 24 weeks after the date of enrollment ]Measurements of liver inflammation and damage
- The activity of CEPT in pmol/mL/min [ Time Frame: 24 weeks after the date of enrollment ]Measurements of liver inflammation and damage
- Plasma cholesteryl ester transfer protein(CETP) concentration in ug/mL [ Time Frame: Baseline ]Measurements of liver inflammation and damage
- The activity of CEPT in pmol/mL/min [ Time Frame: Baseline ]Measurements of liver inflammation and damage
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Meets the diagnostic criteria for type 2 diabetes(1999 WHO criteria).
- Meets the diagnostic criteria for non-alcoholic fatty liver disease (2018 Chinese Medical Association Treatment Guidelines ), and liver ultrasound showed moderate or higher fatty liver.
- Metformin monotherapy for 3 months, but with poor glycemic control (7.5%≤HbA1c≤10.5%))
- Obese or overweight when screening (BMI>24kg/m2);
- 18 years old ≤ age ≤ 70 years old;
- Have a good follow-up compliance, with follow-up months ≥ 24 weeks;
Exclusion Criteria:
- Non-type 2 diabetes: type 1 diabetes, gestational diabetes, or other specific types of diabetes;
- Diabetes patients with acute and chronic complications and serious infections; Pregnant and lactating women;
- Those who have allergies or toxic side effects or contraindications to canagliflozin, pioglitazone and other drugs;
- Active sexually transmitted diseases such as viral hepatitis, AIDS and syphilis, and infectious diseases such as tuberculosis;
- Have a weight change of more than 10% in the 3 months prior to screening;
- Have used other drugs that may affect blood glucose metabolism in the past 2 months, including systemic glucocorticoids (except inhalation or topical use), growth hormone, etc.;
- Have used any sodium-glucose cotransporter-2 (SGLT-2) inhibitor or thiazolidinediones;
- History of more than 2 severe hypoglycemic episodes in the past 1 year;
- History or condition of any of the following: decompensated cardiac insufficiency (NYHA class III or IV); history of unstable angina, myocardial infarction, coronary artery bypass grafting, or coronary stenting; uncontrolled or severe heart rhythm Disorders (such as long QT syndrome, etc.), and evaluated by the investigator to be unsuitable to participate in this clinical trial; currently accompanied by clinically significant urinary tract/reproductive infection, or a history of complicated urinary tract infection, or nearly 6 A history of recurrent urinary tract infections within a month;
- Currently known to have severe osteoporosis, or a history of secondary fractures within the past 1 year;
- Any laboratory tests meet the following criteria: fasting plasma/serum glucose ≥ 15 mmol/L; alanine aminotransferase or aspartate aminotransferase > 3 times the upper limit of normal or total bilirubin > 1.5 times normal Upper limit; hemoglobin <100 g/L; glomerular filtration rate (eGFR) < 60 mL/min/1.73m2; fasting triglycerides > 5.64 mmol/L (500 mg/dL);
- Has received or is receiving any other experimental drug/trial device treatment within the past 3 months;
- Other conditions deemed inappropriate by the investigator to participate in this trial.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05422092
Contact: YAYI HE | 0086-15934880897 | 008099@xjtufh.edu.cn |
Principal Investigator: | YAYI He | First Affiliated Hospital Xi'an Jiaotong University |
Responsible Party: | First Affiliated Hospital Xi'an Jiaotong University |
ClinicalTrials.gov Identifier: | NCT05422092 |
Other Study ID Numbers: |
21YXYJ0111 |
First Posted: | June 16, 2022 Key Record Dates |
Last Update Posted: | September 21, 2022 |
Last Verified: | July 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Liver Diseases Fatty Liver Non-alcoholic Fatty Liver Disease Hepatitis Diabetes Mellitus Diabetes Mellitus, Type 2 Diabetes Complications Inflammation Glucose Metabolism Disorders Metabolic Diseases |
Endocrine System Diseases Pathologic Processes Digestive System Diseases Pioglitazone Canagliflozin Hypoglycemic Agents Physiological Effects of Drugs Sodium-Glucose Transporter 2 Inhibitors Molecular Mechanisms of Pharmacological Action |